Table 1

Characteristics of the study cohort of patients without immune-mediated inflammatory disease (IMID) and according to the subsequent diagnosis of IMID or other condition

All (N=108)New-onset IMID (N=33)No new-onset IMID (N=75)P value*
Inpatients88 (81)13 (39)75 (100)<0.0001
Outpatients20 (19)20 (61)0 (0)
M65 (60)20 (61)45 (60)0.95
F43 (40)13 (39)30 (40)
Vaccine type†0.07
 BNT162b271 (66)18 (54)53 (71)
 mRNA-127311 (10)4 (12)7 (9)
 ChAdOx118 (17)10 (30)8 (11)
 Ad26.COV2.S7 (6)1 (4)6 (8)
 Unknown1 (1)0 (0)1 (1)
Doses received prior to IMID diagnosis
 1NA9NANA
 216
 Full-schedule+booster‡8
Age, mean±SD64±1762±1665±170.42
In-hospital stay, days, mean±SD14±912±915±9
Comorbidities, median (range)3 (0–7)2 (0–7)3 (0–6)0.14
Type of comorbidity, N (%) of patients
Cardiovascular diseases17 (52)49 (65)0.18
Respiratory diseases2 (6)13 (17)0.12
Metabolic disorders11 (33)16 (21)0.18
Gastrointestinal diseases5 (15)18 (24)0.3
Renal diseases2 (6)9 (12)0.34
Neurological diseases4 (12)12 (16)0.6
Endocrine diseases12 (36)24 (32)0.66
Urogenital diseases2 (6)7 (9)0.57
Non-inflammatory MSK diseases3 (9)11 (15)0.43
Neoplasms4 (12)8 (11)0.82
Dermatological diseases1 (3)0 (0)0.54
Psychiatric diseases0 (0)3 (4)0.8
Ophtalmological diseases0 (0)3 (4)0.8
Haematological disorders1 (3)2 (3)0.91
ENT diseases0 (0)3 (4)0.8
  • Values are shown as number (%) of patients unless otherwise stated.

  • BNT162b2, vaccine developed by Pfizer/BioNTech; mRNA1273, vaccine developed by Moderna; ChAdOx1 nCoV-19, vaccine developed by AstraZeneca; Ad26.COV2.S, vaccine developed by Janssen; NA, not applicable; SD, standard deviation; MSK, musculoskeletal; ENT, ear nose throath.

  • *New-onset IMID versus No new-onset IMID. P values were calculated with χ2 test or Mann-Withney U test as needed.

  • †This refers to the dose(s) received prior to the booster vaccination.

  • ‡Booster dose was BNT162b2 in 2/8 patients and mRNA-1273 in 6/8 patients.

  • ENT, ears, nose and throat; MSK, musculoskeletal; N, number; NA, not applicable; SD, standard deviation.